Gilead Sciences, Inc. (ETR:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 107.00B |
| Revenue (ttm) | 26.59B |
| Net Income (ttm) | 5.52B |
| Shares Out | n/a |
| EPS (ttm) | 4.38 |
| PE Ratio | 19.39 |
| Forward PE | 11.77 |
| Dividend | 2.87 (3.34%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | 3,231 |
| Average Volume | 1,769 |
| Open | 82.35 |
| Previous Close | 86.13 |
| Day's Range | 82.04 - 84.99 |
| 52-Week Range | 57.29 - 111.84 |
| Beta | 0.34 |
| RSI | 30.88 |
| Earnings Date | Apr 24, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
NORTHAMPTON, MA / ACCESS Newswire / May 8, 2025 / Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to en...
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
Gilead to invest about $32B in U.S. manufacturing through 2030
Gilead announces $11 billion in new investments in US
Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of ...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 | GILD Stock News
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment –...
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch...
Gilead’s Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi (seladelpar), known as Lyvdelzi in the European Union, is effective and generally wel...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the Europe...
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / At Gilead, we set and achieve bold ambitions in our fight against the world's most devastating diseases. In this installment of The Centrifuge Session...
Gilead: Sure, Why Not, But Not The CDRs
Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus
Stay updated on top pharmaceutical news: Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience
Gilead and Vertex Pharma named among biotech’s tariff safe havens
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM P...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...
Gilead in $202M settlement with DoJ over kickbacks to doctors
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims the drugmaker used speaker programs to pay kickbacks to doctors to induce them to prescribe Gilead...
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's of...
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States
NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has p...
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in pe...
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10,...
SA analyst downgrades: TSLA, AAPL, T, PG, HPE, GILD, LRCX, ARCC
Gilead Sciences: Dividend Investors Must Be Cautious
Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on the stock.